Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Myeloid 21Other hematologic neoplasm 20Plasma cell 1Gastrointestinal 1Classical hematology 1

Conditions

Myelodysplastic Syndromes 1Multiple Myeloma 1Leukemia, Myeloid, Acute 1Colorectal Neoplasms 1

Interventions

Cyclophosphamide 89fludarabine phosphate 77Mycophenolic Acid 53Tacrolimus 52Peripheral Blood Stem Cell Transplantation 50Busulfan 44Whole-Body Irradiation 43Antilymphocyte Serum 41fludarabine 37Cyclosporine 36Filgrastim 32Melphalan 27Methotrexate 26Radiotherapy 23Cord Blood Stem Cell Transplantation 19Methylprednisolone 18Granulocyte Colony-Stimulating Factor 16Sirolimus 14Etoposide 13Alemtuzumab 12thymoglobulin 11sargramostim 11Stem Cell Transplantation 11Rituximab 11Thiotepa 9Azacitidine 8Cytarabine 7Psychiatric Rehabilitation 6Prednisone 6Flow Cytometry 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Myelodysplastic Syndromes × decitabine and cedazuridine drug combination × Plasma cell × Clear all
NCT02649790 2025-03-19

Study of the Safety, Tolerability and Efficacy of KPT-8602 in Participants With Relapsed/Refractory Cancer Indications

Karyopharm Therapeutics Inc

Phase 1/2 Completed
277 enrolled
GastrointestinalMyeloidOther hematologic neoplasmPlasma cell

Multiple Myeloma, Myelodysplastic Syndromes, Colorectal Neoplasms, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡